+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuromuscular Disease Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Neuromuscular Disease Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4832549
  • Report
  • August 2019
  • Region: Global
  • 134 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Novartis AG
  • PTC Therapeutics Inc.
  • Sanofi
  • Sarepta Therapeutics Inc.
  • MORE
Global Neuromuscular Diseases Therapeutics Market: About this market

The neuromuscular diseases therapeutics market analysis considers sales from both biologics and small molecules. Our analysis also considers the sales of neuromuscular diseases therapeutics in Asia, Europe, North America, and ROW. In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing number of special drug designation and clinical efficacy of late-stage pipeline drugs will play a significant role in the biologics segment to maintain its market position. Also, our global neuromuscular diseases therapeutics market report looks at factors such as novel approvals, newborn screening tests, and huge unmet need for neuromuscular diseases therapeutics. However, economic burden on patients, stringent regulatory guidelines, and fast progressive nature of neuromuscular diseases may hamper the growth of the neuromuscular diseases therapeutics industry over the forecast period.

Global Neuromuscular Diseases Therapeutics Market: Overview

Novel approvals

Owing to the rapidly progressive nature of the disease, treatments using drugs are not effective and do not stop the disease progression. This leads the vendors to conduct researches on the development of gene therapies and antisense therapies that can stop the progression of the disease and increase the life expectancy of the patients. Thus, the increasing number of drug approvals will lead to the expansion of the global neuromuscular diseases’ therapeutics market at a CAGR of over 14% during the forecast period.

Technological Advances

One of the major factors that are expected to contribute significantly to the R&D of novel therapeutics for neuromuscular diseases is increasing technological advances. The lack of efficacy and non-disease-modifying drugs for the treatment are leading the vendors to focus on identifying the benefits of regenerative therapies as a potential treatment option. The advent of next generation genetic sequencing technology focuses on sequencing human genome while significantly reducing the associated costs. This results in the market witnessing advance sin the identification of mutated genes that cause neuromuscular diseases. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global neuromuscular diseases therapeutics market is highly concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading neuromuscular diseases therapeutics manufacturers, that include Biogen Inc., Novartis AG, PTC Therapeutics Inc., Sanofi, Sarepta Therapeutics Inc.

Also, the neuromuscular diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Novartis AG
  • PTC Therapeutics Inc.
  • Sanofi
  • Sarepta Therapeutics Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Biologics - Market size and forecast 2018-2023
  • Small molecules - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Technological advances
  • Inherited nature of neuromuscular diseases
  • Increasing research funding
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biogen Inc.
  • Novartis AG
  • PTC Therapeutics Inc.
  • Sanofi
  • Sarepta Therapeutics Inc.
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Global neuromuscular diseases therapeutics market pipeline: Overview
Exhibit 19: Global neuromuscular diseases therapeutics market pipeline: Snapshot
Exhibit 20: Type - Market share 2018-2023 (%)
Exhibit 21: Comparison by type
Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Biogen Inc. - Vendor overview
Exhibit 51: Biogen Inc. - Business segments
Exhibit 52: Biogen Inc. - Organizational developments
Exhibit 53: Biogen Inc. - Geographic focus
Exhibit 54: Biogen Inc. - Key offerings
Exhibit 55: Biogen Inc. - Key customers
Exhibit 56: Novartis AG - Vendor overview
Exhibit 57: Novartis AG - Business segments
Exhibit 58: Novartis AG - Organizational developments
Exhibit 59: Novartis AG - Geographic focus
Exhibit 60: Novartis AG - Segment focus
Exhibit 61: Novartis AG - Key offerings
Exhibit 62: Novartis AG - Key customers
Exhibit 63: PTC Therapeutics Inc. - Vendor overview
Exhibit 64: PTC Therapeutics Inc. - Business segments
Exhibit 65: PTC Therapeutics Inc. - Organizational developments
Exhibit 66: PTC Therapeutics Inc. - Key offerings
Exhibit 67: PTC Therapeutics Inc. - Key customers
Exhibit 68: Sanofi - Vendor overview
Exhibit 69: Sanofi - Business segments
Exhibit 70: Sanofi - Organizational developments
Exhibit 71: Sanofi - Geographic focus
Exhibit 72: Sanofi - Segment focus
Exhibit 73: Sanofi - Key offerings
Exhibit 74: Sanofi - Key customers
Exhibit 75: Sarepta Therapeutics Inc. - Vendor overview
Exhibit 76: Sarepta Therapeutics Inc. - Business segments
Exhibit 77: Sarepta Therapeutics Inc. - Organizational developments
Exhibit 78: Sarepta Therapeutics Inc. - Geographic focus
Exhibit 79: Sarepta Therapeutics Inc. - Key offerings
Exhibit 80: Sarepta Therapeutics Inc. - Key customers
Exhibit 81: Validation techniques employed for market sizing
Exhibit 82: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Novartis AG
  • PTC Therapeutics Inc.
  • Sanofi
  • Sarepta Therapeutics Inc.
  • MORE
The following companies are recognised as the key players in the global neuromuscular diseases therapeutics market: Biogen Inc., Novartis AG, PTC Therapeutics Inc., Sanofi, Sarepta Therapeutics Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the technological advances.”

According to the report, one of the major drivers for this market is the novel approvals.

Further, the report states that one of the major factors hindering the growth of this market is the economic burden on patients.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Biogen Inc.
  • Novartis AG
  • PTC Therapeutics Inc.
  • Sanofi
  • Sarepta Therapeutics Inc.
Note: Product cover images may vary from those shown
Adroll
adroll